A randomized phase II study of everolimus for advanced pancreatic neuroendocrine tumors in Chinese patients.

Yao J, Wang JY, Liu Y, Wang B, Li YX, Zhang R, Wang LS, Liu L.

DOI: 10.1007/s12032-014-0251-x
Published: 2014-11-14
Container: Med Oncol
Publisher: Not recorded
Open access: no

Credibility signals

serious concern Score 8/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
serious concernRetraction Watch retraction: 1 retraction notice matched this DOI. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s12032-014-0251-x,
  title = {A randomized phase II study of everolimus for advanced pancreatic neuroendocrine tumors in Chinese patients.},
  author = {Yao J and  Wang JY and  Liu Y and  Wang B and  Li YX and  Zhang R and  Wang LS and  Liu L.},
  year = {2014},
  journal = {Med Oncol},
  doi = {10.1007/s12032-014-0251-x},
  url = {https://doi.org/10.1007/s12032-014-0251-x}
}

RIS

TY  - JOUR
TI  - A randomized phase II study of everolimus for advanced pancreatic neuroendocrine tumors in Chinese patients.
AU  - Yao J
AU  -  Wang JY
AU  -  Liu Y
AU  -  Wang B
AU  -  Li YX
AU  -  Zhang R
AU  -  Wang LS
AU  -  Liu L.
PY  - 2014
JO  - Med Oncol
DO  - 10.1007/s12032-014-0251-x
UR  - https://doi.org/10.1007/s12032-014-0251-x
ER  -

APA

J, Y., JY, W., Y, L., B, W., YX, L., R, Z., LS, W., & L., L. (2014). A randomized phase II study of everolimus for advanced pancreatic neuroendocrine tumors in Chinese patients.. Med Oncol. https://doi.org/10.1007/s12032-014-0251-x

Source records

europe-pmc · retrieved 2026-11-11T00:53:46.215Z